Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Chemotherapy in Neoadjuvant Esophageal Cancer
NCT03946969Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2019
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Safety and feasibility at 20 months. Status: unknown.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03946969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946969.